|本期目录/Table of Contents|

[1]王婷,郑荣秀,刘靓,等.重组人生长激素对矮身材儿童身高增长疗效分析及预测模型的建立[J].天津医科大学学报,2018,24(03):232-235,244.
　WANG Ting,ZHENG Rong-xiu,LIU Liang,et al.Effect of recombinant human growth hormone therapy on GHD and ISS patients and establishment of prediction model[J].Journal of Tianjin Medical University,2018,24(03):232-235,244.
点击复制

重组人生长激素对矮身材儿童身高增长疗效分析及预测模型的建立(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
24卷
期数:
2018年03期
页码:
232-235,244
栏目:
出版日期:
2018-05-20

文章信息/Info

Title:
Effect of recombinant human growth hormone therapy on GHD and ISS patients and establishment of prediction model
作者:
王婷; 郑荣秀; 刘靓; 刘朔
天津医科大学总医院儿科，天津 300052
Author(s):
WANG Ting; ZHENG Rong-xiu; LIU Liang; LIU Shuo
Department of Pediatrics, General Hospital, Tianjin Medical University， Tianjin 300052, China
关键词:
重组人生长激素; 生长激素缺乏症; 特发性矮小症; 预测模型
Keywords:
recombinant human growth hormone;  growth hormone deficiency;  idiopathic short stature;  prediction model
分类号:
R58
DOI:
-
文献标志码:
A
摘要:
目的：观察重组人生长激素(rhGH)对矮身材儿童治疗效果，建立rhGH疗效预测模型,为治疗提供依据。方法：搜集因矮身材就诊的64例患儿，其中生长激素缺乏症（GHD）38例，特发性矮小症（ISS）26例，予rhGH治疗6个月，观察身高增长情况（ΔHt）、生长速率（GV）、身高差SDS（ΔHtSDS）等指标。以治疗6个月生长速率（Y）为因变量，初始胰岛素样生长因子-1值（X4），初始IGF-ISDS值（X5）、初始身高（X6）、治疗3个月身高（X10）为自变量，采用多元线性回归方法建立疗效预测模型，并前瞻性观察5例患儿，对预测模型进行验证。结果：经rhGH治疗，GHD及ISS生长均较前增快，且就ΔHt、ΔHtSDS、GV来看，前3个月治疗效果较4～6个月效果好；经rhGH治疗，GHD与ISS的治疗效果差异无统计学意义。前瞻性研究5例矮身材儿童，对模型进行验证，患儿经rhGH治疗6个月后生长速率实测值与预测值分别为（10.37±1.95）cm/年和（9.81±1.75）cm/年，二者配对t检验差异无统计学意义（P>0.05）。结论：无论是GHD还是ISS，经rhGH治疗后前3个月较4～6个月增长较快，且二者治疗效果无差异。建立的预测模型R2高，学生化残差几乎接近0，模型拟合度高，预测模型有应用价值。
Abstract:
Objective: To investigate the differences in efficacy of rhGH in treating GHD and ISS and to establish the forecast model of rhGH efficacy to guide treatment. Methods： Thirty-eight children with GHD and 26 children with ISS were enrolled in the study. Patients received rhGH treatment for at least six months. The ΔHt, GVand ΔHtSDS were observed. The effect and influencing factors of their therapy were analyzed. Then prediction models were established by multiple liner regression. Meanwhile, 5 cases were prospectively followed up for at least six months to verify the model. Results： GHD and ISS patients were taller after treatment with rhGH. In terms of ΔHt, ΔHtSDS and GV, the first three months were better than the last three months. The difference was statistically significant (P<0.05). After treatment with rhGH for 0-3 months and 4-6 months with ΔHt， ΔHtSDS and GV, the difference in therapeutic effect on GHD and ISS was not statistically significant (P> 0.05). R2=0.727. Five cases of short stature children were verified. After 6 months of rhGH treatment, the measured values and predicted values were(10.37±1.95) cm/year and （9.81±1.75） cm/year, respectively, and the difference was not statistically significant (P>0.05). Conclusion： Significant effect is obtained in the first 3 months since the treatment.RhGH therapy effect has no difference between GHD and ISS. Prediction model has application value.

参考文献/References:

[1] Ross J L, Lee P A, Gut R, et al. Increased height standard deviation scores in response to growth hormone therapy to near-adult height in older children with delayed skeletal maturation: results from the ANSWER Program[J]. Int J Pediatr Endocrinol, 2015,2015(1):1
[2] Im M, Kim Y D, Han H S. Effect of growth hormone treatment on children with idiopathic short stature and idiopathic growth hormone deficiency[J]. Ann Pediatr Endocrinol Metab,2017,22(2):119
[3] Sotos J F, Tokar N J. Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit[J]. Int J Pediatr Endocrinol,2014(1):15
[4] Leger J, Mohamed D, Dos Santos S, et al. Impact of the underlying etiology of growth hormone deficiency on serum IGF-I SDS levels during GH treatmentinchildren[J]. Horm Res Paediatr,2017,88(1):120
[5] 刘洋洋,戴秀华,庞淑兰,等. 重组人生长激素对生长激素缺乏症患儿增高疗效的影响因素分析及预测模型的建立[J].中国煤炭工业医学杂志,2017,20(7):822
[6] 李辉,季成叶,宗心南,等. 中国0-18岁儿童,青少年身高,体重的标准化生长曲线[J].中华儿科杂志,2009,47(7):487
[7] 中华医学会儿科学分会内分泌遗传代谢学组.矮身材儿童诊治指南[J].中华医学信息导报,2008,23(24):20
[8] Jung A M, Zenker M, Lissewski C A, et al. Genetic polymorphisms as predictive markers of response to growth hormone therapy in children with growth hormone deficiency[J].Klin Padiatr,2017, 229(5):267
[9] 中华医学会儿科学分会内分泌遗传代谢学组,《中华儿科杂志》编辑委员会,梁雁.基因重组人生长激素儿科临床规范应用的建议[J].中华儿科杂志,2013,51(6):426
[10] 朱顺姬.CHN图谱法评估儿童左右手骨龄发育研究[J].中国全科医学,2017,20(S1):143
[11] Polak M, Blair J, Kotnik P, et al. Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet (R) International Outcome Study[J].Eur J Endocrinol,2017,177(5):421
[12] Guven B, Can M, Mungan G, et al. Reference values for serum levels of insulin-like growth factor 1 (IGF-1) and IGF-binding protein 3 (IGFBP-3) in the West Black Sea region of Turkey[J]. Scand J Clin Lab Invest,2013,73(2):135
[13] Cole T J, Freeman J V, Preece M A. Body mass index reference curves for the UK,1990[J].Arch Dis Child,1995,73(1):25
[14] 程炳娟,刘戈力,李宁,等. 特发性矮小生长激素受体外显子3基因多态性与生长激素轴的关系[J].天津医药,2016,44(01):78
[15] De Ridder M A. Stijnen T, Hokken-Koelega A C. Validation and calibration of the Kabipharmacia international growth study prediction model for children with idiopathic growth hormone deficiency[J]. J ClinEndocrinol Metab,2003,88(3):1223
[16] Sch?觟nau E,Westermann F, Rauch F, et al. A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency[J]. Eur J Endocrinol,2001, 144(1):13
[17] Seo J Y, Yun K A, Hwang J W, et al. The relationship between parents’ perception about child's height and psychopathology in community children with relatively short stature[J]. Endocr Rev,2010, 31(3):79
[18] 张雪霜,熊丰,朱岷,等. 重组人生长激素治疗不同病因矮小症患儿效果观察[J].第三军医大学学报,2016,38(16):1889.
[19] 郭春艳,贺波,呼延佳,等. 重组人生长激素对身材矮小儿童增高疗效的相关影响因素分析[J].中国儿童保健杂志,2015,23(2):147
[20] Jeong H R, Kwon E B, Shim Y S, et al. Comparative study of growth hormone treatment in children with idiopathic short stature and growth hormone deficiency[J]. Curr Drug Metab,2015,16(10):940
[21] Yassin M, Soliman A T, Desanctis V. Growth hormone-insulin-like growth factor-I axis and bone mineral density in adults with thalassemia major[J]. Haematologica,2014,99(1):737
[22] Trovato L, Riccomagno S, Prodam F, et al. Isolated GHD: investigation and implication of JAK/STAT related genes before and after rhGH treatment[J]. Pituitary,2012,15(4):482
[23] 丁道芳,李玲慧,宋奕,等. MAPK-ERK1/2信号通路调控成骨性基因表达和细胞增殖[J].南方医科大学学报,2013,33(10):1432
[24] 赵巧飞. 生长激素长期刺激导致肝脏生长激素不敏感效应的研究[D]. 南方医科大学内科学（消化系病）, 2016
[25] Smyczynska J, Hilczer M, Smyczynska U A, et al. Neural network models - a novel tool for predicting the efficacy of growth hormone (GH) therapy in children with short stature[J]. Neuro Endocrinol Lett,2015,36(4):348
[26] 武华红,李辉,孙淑英. 重组人生长激素治疗生长激素缺乏症疗效分析及预测模型探讨[J].中国实用儿科杂志,2011,26(4):289
[27] 李鑫,班博,乔建敏,等. 矮小症生长激素受体基因外显子3多态性与重组人生长激素疗效相关性的Meta分析[J].中国优生与遗传杂志,2017,25(1):14

相似文献/References:

[1]许庆玲,张淑欣,郑荣秀.重组人生长激素治疗德朗热综合征1例[J].天津医科大学学报,2021,27(01):88.
[2]刘祖娴,姜丽红,刘戈力,等.Potocki-Lupski综合征及重组人生长激素治疗随诊1例报告[J].天津医科大学学报,2023,29(03):326.

备注/Memo

备注/Memo:
文章编号 1006-8147(2018)03-0232-04
作者简介 王婷（1991-），女，硕士在读，研究方向：儿科内分泌学；通信作者：郑荣秀，E-mail:18622815720@163.com。
更新日期/Last Update: 2018-05-20